Momenta Pharmaceuticals
Market Cap
€2.8b
Last Updated
2020/03/28 20:34 UTC
Data Sources
Company Financials +
Executive Summary
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States.
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Flawless balance sheet with limited growth.
Similar Companies
Share Price & News
How has Momenta Pharmaceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: LZ1's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
2.7%
LZ1
11.3%
DE Biotechs
7.1%
DE Market
1 Year Return
84.0%
LZ1
-5.1%
DE Biotechs
-17.5%
DE Market
Return vs Industry: LZ1 exceeded the German Biotechs industry which returned -5.4% over the past year.
Return vs Market: LZ1 exceeded the German Market which returned -17.5% over the past year.
Shareholder returns
| LZ1 | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.7% | 11.3% | 7.1% |
| 30 Day | -14.3% | -8.0% | -20.0% |
| 90 Day | 26.7% | -22.7% | -26.1% |
| 1 Year | 84.0%84.0% | -4.9%-5.1% | -15.0%-17.5% |
| 3 Year | 84.0%84.0% | 17.7%16.4% | -18.8%-25.8% |
| 5 Year | 64.8%64.8% | -5.1%-7.5% | -17.9%-29.2% |
Price Volatility Vs. Market
How volatile is Momenta Pharmaceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Valuation
Is Momenta Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
6.69x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LZ1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LZ1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LZ1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: LZ1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LZ1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LZ1 is overvalued based on its PB Ratio (6.7x) compared to the DE Biotechs industry average (3.6x).
Next Steps
Future Growth
How is Momenta Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?
14.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LZ1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LZ1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LZ1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LZ1's revenue (46.7% per year) is forecast to grow faster than the German market (4.2% per year).
High Growth Revenue: LZ1's revenue (46.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LZ1 is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Momenta Pharmaceuticals performed over the past 5 years?
-27.8%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: LZ1 is currently unprofitable.
Growing Profit Margin: LZ1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: LZ1 is unprofitable, and losses have increased over the past 5 years at a rate of -27.8% per year.
Accelerating Growth: Unable to compare LZ1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LZ1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).
Return on Equity
High ROE: LZ1 has a negative Return on Equity (-63.82%), as it is currently unprofitable.
Next Steps
Financial Health
How is Momenta Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LZ1's short term assets ($539.1M) exceed its short term liabilities ($106.1M).
Long Term Liabilities: LZ1's short term assets ($539.1M) exceed its long term liabilities ($57.8M).
Debt to Equity History and Analysis
Debt Level: LZ1 is debt free.
Reducing Debt: LZ1 has not had any debt for past 5 years.
Balance Sheet
Inventory Level: LZ1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if LZ1's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LZ1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: LZ1 has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of -17.4% each year.
Next Steps
Dividend
What is Momenta Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LZ1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate LZ1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LZ1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LZ1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LZ1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.4yrs
Average management tenure
CEO
Craig Wheeler (59yo)
13.5s
Tenure
US$4,610,270
Compensation
Mr. Craig A. Wheeler has been the Chief Executive Officer and President of Momenta Pharmaceuticals Inc. since September 12, 2006 and August 22, 2006, respectively. Mr. Wheeler has been an Executive Directo ...
CEO Compensation Analysis
Compensation vs Market: Craig's total compensation ($USD4.61M) is about average for companies of similar size in the German market ($USD3.79M).
Compensation vs Earnings: Craig's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 13.5yrs | US$4.61m | 0.50% $13.7m | |
| Chief Financial & Business Officer | 0.17yr | US$2.37m | 0.12% $3.3m | |
| Chief Scientific Officer | 1.42yrs | US$2.18m | 0.011% $307.2k | |
| Chief Medical Officer & Senior VP of Development | 2.75yrs | US$2.31m | 0.024% $655.3k | |
| Consultant | 1.42yrs | US$1.98m | 0.019% $518.2k | |
| Co-Founder & Consultant | no data | US$1.52m | 0.42% $11.5m | |
| Principal Accounting Officer | 0.17yr | no data | no data | |
| Vice President of Investor Relations & Communications | 1.17yrs | no data | no data | |
| Chief Legal Officer | 1.42yrs | no data | 0.0084% $233.4k | |
| Chief Human Resources & Infrastructure Officer | no data | no data | 0.044% $1.2m |
1.4yrs
Average Tenure
52yo
Average Age
Experienced Management: LZ1's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 13.5yrs | US$4.61m | 0.50% $13.7m | |
| Chairman | 1.75yrs | US$284.10k | 0.028% $784.6k | |
| Member of Regulatory Advisory Board | no data | no data | no data | |
| Member of Regulatory Advisory Board | no data | no data | no data | |
| Independent Director | 4.17yrs | US$268.60k | 0.012% $339.2k | |
| Independent Director | 3.75yrs | US$266.60k | 0.0068% $187.6k | |
| Member of Regulatory Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Regulatory Advisory Board | no data | no data | no data | |
| Independent Director | 3.5yrs | US$271.10k | 0.0088% $242.8k |
3.8yrs
Average Tenure
62.5yo
Average Age
Experienced Board: LZ1's board of directors are considered experienced (3.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.6%.
Top Shareholders
Company Information
Momenta Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Momenta Pharmaceuticals, Inc.
- Ticker: LZ1
- Exchange: DB
- Founded: 2001
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.063b
- Listing Market Cap: US$2.763b
- Shares outstanding: 114.76m
- Website: https://www.momentapharma.com
Number of Employees
Location
- Momenta Pharmaceuticals, Inc.
- 301 Binney Street
- Cambridge
- Massachusetts
- 2142
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MNTA | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Jun 2004 |
| LZ1 | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Jun 2004 |
Biography
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company’s biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.Â
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/03/28 20:34 |
| End of Day Share Price | 2020/03/27 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.